Table 1.
ncRNA | PRO-apoptotic role | Cellular/animal model | Relevant references (original papers) |
---|---|---|---|
Let-7 |
• Inhibition of BCL2L1 • Upregulation of BAK and BAX, and downregulation of BCL-xL |
• Colorectal cancer • Leukemia |
Mizuno et al.46 Huang et al.47 |
miR-15/16 | • Repression of BCL-2 and BMI1 |
• Chronic lymphatic leukemia • Mantle cell lymphoma |
Cimmino et al.52 Teshima et al.53 |
miR-34 | • Regulation of proteins involved in cell death: BCL-2, BIRC5 (Survivin), CREB, and YY1 |
• Pancreatic cancer • Myeloid leukemia • Neuroblastoma • Laryngeal squamous cell cancer |
Chang et al.67 Pigazzi et al.68 Chen et al.69 Shen et al.70 |
miR-29 | • Repression of MCL-1 expression | • Acute myeloid leukemia | Garzon et al.76 |
GAS5 | • Induction of apoptosis in a mouse model | • Brest cancer (mouse) | Mourtada-Maarabouni et al.103 |
MEG3 | • Induction of p53 | • Colorectal cancer | Zhou et al.108 |
NIKLA | • Activation of apoptosis in tumor-specific CTLs | • Breast cancer and lung cancer | Huang et al.113 |
NEAT1a | • Enhanced apoptosis after DNA damage | • Chronic lymphocytic leukemia | Blume et al.116 |
circFOXO3 | • Increased PUMA expression | • Breast cancer (mouse) | Du et al.147 |
ncRNA | ANTI-apoptotic role | Cellular/animal model | Relevant references (original papers) |
---|---|---|---|
miR-21 | • expression of pro-apoptotic genes: APAF11, PDCD4, RHOB, and FASLG | • Non-small cell lung cancer | Hatley et al.84 |
miR-155 | • Repression of SHIP-1 |
• B lymphocytes • Hematopoietic cells |
Costinean et al.91 O’Connell et al.92 |
miR-221 | • Increased apoptosis and cell-cycle arrest | • Hepatocellular carcinoma | Park et al.98 |
CCAT | • Interaction with p63 and SOX2 | • Squamous cell carcinoma | Jiang et al.123 |
FAL1 | • Interaction with BMI1 | • Pan-cancer database | Hu et al.128 |
PVT1 | • Downregulation of Caspase-7, Caspase-9, and PARP | • Nasopharyngeal carcinoma | He et al.132 |
aControversial role since NEAT1 has also been correlated to an oncogenic activity in some tumor types.